Celon Pharma S.A. (WSE:CLN)
Poland
· Delayed Price · Currency is PLN 21.35
-0.05 (-0.23%)
Mar 9, 2026, 4:48 PM CET
Celon Pharma Revenue
Celon Pharma had revenue of 71.13M PLN in the quarter ending September 30, 2025, with 39.34% growth. This brings the company's revenue in the last twelve months to 225.60M, up 7.29% year-over-year. In the year 2024, Celon Pharma had annual revenue of 205.55M, down -4.25%.
Revenue (ttm)
225.60M
Revenue Growth
+7.29%
P/S Ratio
5.11
Revenue / Employee
398.58K
Employees
566
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 205.55M | -9.12M | -4.25% |
| Dec 31, 2023 | 214.66M | 20.78M | 10.72% |
| Dec 31, 2022 | 193.89M | -2.20M | -1.12% |
| Dec 31, 2021 | 196.09M | 38.64M | 24.54% |
| Dec 31, 2020 | 157.45M | 55.20M | 53.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Diagnostyka | 2.30B |
| NEUCA | 13.34B |
| Synektik Spólka Akcyjna | 706.45M |
| Voxel | 568.83M |
| Selvita | 373.90M |
| Centrum Medyczne ENEL-MED | 820.59M |
| Ryvu Therapeutics | 90.41M |
| Captor Therapeutics Spolka Akcyjna | 7.57M |
Celon Pharma News
- 1 year ago - Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease - Benzinga